Objectives Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non-small-cell lung cancer remain under discussion. Pathological features are the main determinant of follow-up therapy but have limited ability to identify patients at risk of recurrence. Increasingly, molecular markers are incorporated into clinical decision-making, including measures of tumor growth. The CCP score is a quantitative, molecular measure of proliferation derived from the RNA expression of 31 cell cycle genes and a component of the molecular prognostic score (mPS). The mPS score is a linear combination of CCP score and pathological stage. CCP score and mPS are independent predictors of survival in resected lung adenocarcinoma. Materials and methods CCP scores were determined by RT-qPCR for 318 patients diagnosed with stage I–II lung adenocarcinoma. Association of mPS and CCP score with distant recurrence and lung-cancer specific survival was assessed in Cox proportional hazards regression models adjusted for age, gender, tumor size, pathological stage and pleural invasion. Distant recurrence-free survival and lung-cancer specific survival by mPS risk group were calculated by Kaplan-Meier survival analysis. Results CCP scores were obtained for 205 stage I and 84 stage II patients. CCP score and mPS were independent markers of distant recurrence (CCP: HR 1.62, 95%CI 1.15-2.29, p = 0.0055; mPS: HR 2.22, 95%CI 1.11-4.44, p = 0.023). Patients with low mPS tumors were at significantly reduced risk of distant recurrence (log-rank p = 4.2 × 10−5). Among stage I patients, stratification by mPS identified a patient group with increased risk of distant recurrence (36%, 95%CI 28–46%, log-rank p = 0.0011) Conclusions The molecular prognostic score stratifies early-stage, resected lung cancer patients for risk of distant recurrence and could be useful to inform treatment and surveillance decisions.

Prediction of distant recurrence in resected stage I and II lung adenocarcinoma / Aramini, Beatrice; Casali, Christian; Stefani, Alessandro; Bettelli, Stefania; Wagner, Susanne; Sangale, Zaina; Hughes, Elisha; Lanchbury, Jerry S.; Maiorana, Antonino; Morandi, Uliano. - In: LUNG CANCER. - ISSN 0169-5002. - ELETTRONICO. - 101:(2016), pp. 82-87. [10.1016/j.lungcan.2016.09.005]

Prediction of distant recurrence in resected stage I and II lung adenocarcinoma

Aramini, Beatrice;Casali, Christian;Stefani, Alessandro;Bettelli, Stefania;Maiorana, Antonino;Morandi, Uliano
2016

Abstract

Objectives Optimal procedures for adjuvant treatment and post-surgical surveillance of resected non-small-cell lung cancer remain under discussion. Pathological features are the main determinant of follow-up therapy but have limited ability to identify patients at risk of recurrence. Increasingly, molecular markers are incorporated into clinical decision-making, including measures of tumor growth. The CCP score is a quantitative, molecular measure of proliferation derived from the RNA expression of 31 cell cycle genes and a component of the molecular prognostic score (mPS). The mPS score is a linear combination of CCP score and pathological stage. CCP score and mPS are independent predictors of survival in resected lung adenocarcinoma. Materials and methods CCP scores were determined by RT-qPCR for 318 patients diagnosed with stage I–II lung adenocarcinoma. Association of mPS and CCP score with distant recurrence and lung-cancer specific survival was assessed in Cox proportional hazards regression models adjusted for age, gender, tumor size, pathological stage and pleural invasion. Distant recurrence-free survival and lung-cancer specific survival by mPS risk group were calculated by Kaplan-Meier survival analysis. Results CCP scores were obtained for 205 stage I and 84 stage II patients. CCP score and mPS were independent markers of distant recurrence (CCP: HR 1.62, 95%CI 1.15-2.29, p = 0.0055; mPS: HR 2.22, 95%CI 1.11-4.44, p = 0.023). Patients with low mPS tumors were at significantly reduced risk of distant recurrence (log-rank p = 4.2 × 10−5). Among stage I patients, stratification by mPS identified a patient group with increased risk of distant recurrence (36%, 95%CI 28–46%, log-rank p = 0.0011) Conclusions The molecular prognostic score stratifies early-stage, resected lung cancer patients for risk of distant recurrence and could be useful to inform treatment and surveillance decisions.
2016
6-set-2016
101
82
87
Prediction of distant recurrence in resected stage I and II lung adenocarcinoma / Aramini, Beatrice; Casali, Christian; Stefani, Alessandro; Bettelli, Stefania; Wagner, Susanne; Sangale, Zaina; Hughes, Elisha; Lanchbury, Jerry S.; Maiorana, Antonino; Morandi, Uliano. - In: LUNG CANCER. - ISSN 0169-5002. - ELETTRONICO. - 101:(2016), pp. 82-87. [10.1016/j.lungcan.2016.09.005]
Aramini, Beatrice; Casali, Christian; Stefani, Alessandro; Bettelli, Stefania; Wagner, Susanne; Sangale, Zaina; Hughes, Elisha; Lanchbury, Jerry S.; Maiorana, Antonino; Morandi, Uliano
File in questo prodotto:
File Dimensione Formato  
Prediction of distant recurrence in resected stage I and II lung adenocarcinoma.pdf

Accesso riservato

Descrizione: articolo principale
Tipologia: Versione pubblicata dall'editore
Dimensione 696.03 kB
Formato Adobe PDF
696.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1117776
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 20
social impact